The K562 cell line serves as a model to study the molecular mechanisms associated with leukemia differentiation. We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage. Electronic microscopy analysis showed that K562 cells treated with PMA þ SB exhibited characteristic features of physiological megakaryocytic differentiation including the presence of vacuoles and demarcation membranes. Differentiation was also accompanied by a net increase in megakaryocytic markers and a reduction of erythroid markers, especially when both effectors were present. PMA effect was selectively mediated by new PKC isoforms. Differentiation of K562 cells by the combination of PMA and SB required Erk1/2 activation, a threshold of JNK activation and p38 MAPK inhibition. Interestingly, higher concentrations of SB, which drastically activated JNK, blocked megakaryocytic differentiation, and considerably increased cell death in the presence of PMA. c-DNA microarray membranes and PCR analysis allow us to identify a set of genes modulated during PMAinduced K562 cell differentiation. Several gene families identified in our screening, including ephrins receptors and some angiogenic factors, had never been reported so far to be regulated during megakaryocytic differentiation.
Introduction
Hematopoiesis in vertebrates is a complex, multistep and highly ordered process that takes place in specific organs during development. It requires cell-specific gene expression that directs growth and differentiation of a pluripotent cell to acquire the phenotype changes of mature blood cells. The human chronic myelogenous (CML) cell line K562 has been used extensively as a model for the study of leukemia differentiation (Lam et al., 2000; Matsumura et al., 2000; Racke et al., 2001) . K562 behaves as pluripotent hematopoietic precursor, expressing in undifferentiated conditions markers for both erythroid and megakaryocytic lineages. K562 cells can undergo further differentiation in both megakaryocytic and erythroid lineages depending on the stimulus. Phorbol esters such as PMA-stimulated megakaryocytic differentiation (Shelly et al., 1998; Kim et al., 2001; Dorsey et al., 2002; Pettiford and Herbst, 2003) , whereas hemin, hydroxyurea, Ara-C or as reported more recently imatinib mesylate (gleevec) induced erythroid differentiation of this cell line (Belhacene et al., 1998; Park et al., 2001; Jacquel et al., 2003; Kawano et al., 2004a, b) . Megakaryocytic differentiation of K562 cells induced by PMA mimics, in part, the physiologic process that takes place in the bone marrow in response to a variety of stimuli (Long et al., 1990) . This differentiation process is accompanied by changes in cell morphology, adhesive properties, cell growth arrest, endomitosis, and acquisition of specific markers of megakaryocytes such as CD41, CD61, and CD10 (Belhacene et al., 1998; Herrera et al., 1998; Dorsey et al., 2002) . The signaling cascade that leads to PMA-induced differentiation of K562 cells has been partially described. and a general role of PKC in the megakaryocyte differentiation process has been previously established (Murray et al., 1993; Goldfarb et al., 2001; Racke et al., 2001) . The PKC family comprises at least 11 isotypes classified into three subgroups according to their structure and cofactor requirements: Conventionnal PKCs (PKC: PKCa, PKCb 1 , PKCb 2 , and PKCg), novel PKCs (PKCd, PKCe, PKCZ, PKCy , and PKCm) and atypical PKCs (PKCz, PKCi/l) (Ron and Kazanietz, 1999; Nalefski and Newton, 2001; Parker and Murray-Rust, 2004) . Even though a general role for PKC in megakaryocytic differentiation of K562 cells has been established, the nature of the PKC isotypes, the signaling pathways downstream of PKC activation, and the modulation of gene expression that follows from this process are currently poorly determined.
More recently, several reports have also highlighted the role of the MEK/MAPK pathway in the modulation of megakaryocytic differentiation downstream from PKC activation (Racke et al., 1997; Rouyez et al., 1997) . As previously mentioned, Erk1/2 activation is required for PMA-induced differentiation of K562 cells towards the megakaryocytic lineage, while both inhibition of this pathway and activation of the p38 MAPK are likely to play a role in signal transduction mechanisms leading to erythroid differentiation (Park et al., 2001; Huang et al., 2004; Uddin et al., 2004) . Although Erk1/2 activation is thought to be important for differentiation of K562 cells towards the megakaryocytic lineage, the role of other pathways such as p38 MAPK and JNK is far less documented. In the present study, using K562 cells as a cellular model of CML differentiation towards different lineages, we established the main requirements for PMAmediated megakaryocytic differentiation. We show that PMA induced a PKC-dependent, Erk1/2, JNK, p38 MAPK-dependent and PI3K-independent differentiation program in K562 cells. More precisely, it results from our data that upon PMA stimulation, new PKC isotypes trigger Erk1/2 activation, and moderate JNK stimulation and p38 MAPK inhibition. The role of p38 MAPK inhibition in the process of megakaryocytic differentiation seems particularly important since two inhibitors of this pathway were shown to drastically increase differentiation towards the megakaryocytic lineage. Moreover, we reported that inhibition of the p38 MAPK pathway is necessary for both a quantitative and qualitative megakaryocytic differentiation (i.e. nearly 100% of cells differentiate and many of them exhibit features of terminal megakaryocyte differentiation). By contrast, higher concentrations of p38 MAPK inhibitors markedly reduced differentiation and induced cell death in PMA-treated cells. Finally, c-DNA array analysis allows us to characterize a panel of genes whose expression was strikingly modulated by PMA. Some of these genes have never been reported so far to be expressed or involved during megakaryocytic differentiation. The potential role of these new identified genes in the regulation of the differentiation programs of K562 cells are discussed.
Results
Low concentrations of the p38 MAPK inhibitor SB202190 favor megakaryocytic differentiation of K562 cells while higher doses inhibit it Exposure of K562 cells to PMA induces megakaryocytic differentiation. This differentiation program is characterized by morphological modifications, easily detectable by phase contrast microscopy or after MayGrunwald-Giemsa staining ( Figure 1A) . After 48 h of treatment, a net increase in cell size and the presence of some vacuoles were observed ( Figure 1A , a-e). In a first series of experiments, based on the use of pharmacological inhibitors, we established that GF109203X (GFX), an inhibitor of new and conventional PKCs ( Figure 1A ), and to a lesser extent Uo126 and PD98059, two MEK1 inhibitors (not shown), inhibited PMAmediated megakaryocytic differentiation of K562 cells. By contrast, LY294002 and wortmannin, two inhibitors of PI3 K pathway, and Go¨6976, an inhibitor of conventional PKCs, had no effect (not shown). Interestingly, the morphological modifications characteristic of megakaryocytic differentiation appeared earlier when 5 mM of SB202190 (SB), an inhibitor of p38 MAPK, was added concomitantly to PMA ( Figure 1A , b-e). A more differentiated phenotype was also observed in MEG-01 cells incubated in the presence of the combination PMA þ SB (not shown). Neither SB nor GFX alone induced differentiation of K562 cells. Figure 1B illustrates a quantitative analysis of megakaryocyte differentiation as a function of time in the presence of PMA and different inhibitors of various signaling pathways. At 24 h no differentiation was detected in the presence of PMA, while approximately 20% of the cells already exhibited morphological evidence of differentiation in the presence of PMA þ SB. More than 90% of K562 cells differentiated towards the megakaryocytic lineage after 72 h in the presence of the combination of PMA and SB. Electronic microscopy analysis allowed us to better analyse the ultrastructural modifications in differentiated K562 cells. In the presence of PMA and SB, giant cells (30-50 mm) containing huge vacuoles, as compared to cells treated with PMA alone, were visualized ( Figure 1C , a-c). Larger magnifications allow us in certain circumstances to evidence some structures inside these vacuoles (not shown). Numerous cellular structures resembling demarcation membranes were also visible inside the cytosol of differentiating megakaryocytes, more particularly in cells that received the PMA þ SB combination ( Figure 1C, c) . These membranes have many things in common with the demarcation membranes found in the course of physiological megakaryocytic differentiation (Cramer et al., 1997) . Finally, higher concentrations of SB (20-40 mM) were found to inhibit PMA-mediated differentiation and to induce K562 cell apoptosis in the presence of the phorbol ester as judged by both morphological analysis and caspase assay (Figure 2a and b) .
Induction and repression of specific differentiation markers during differentation of K562 cells by PMA A representative flow cytometric analysis for the expression of CD44, CD41 and CD10, is shown in Figure 3 . CD44 expression was used here as a positive control of PMA stimulation. CD41 and CD10 have been previously reported to represent specific markers of megakaryocytic differentiation (Belhacene et al., 1998; Herrera et al., 1998; Dorsey et al., 2002) . CD44 expression drastically increased after 48 h in the presence of PMA, an effect abrogated by GFX. PMA treatment resulted in a significant augmentation of both CD41 and CD10 expression, which was further increased by SB ( Figure 3a) . As expected, GFX abrogated the PMAmediated increase in CD41 and CD10 expression. We also investigated by RT-PCR, the expression of mRNA specific for megakaryocytic or erythroid differentiation. As shown in Figure 3b , PMA induced CD10 and Signaling pathways in leukemia cell differentiation A Jacquel et al GATA-2 mRNA expression, two markers of megakaryocytic differentiation, while it reduced the expression of several erythroid markers including glycophorin A, g-globin, and CD36. Interestingly, in the presence of SB, both induction of megakaryocytic and repression of erythroid markers by PMA were significantly increased (Figure 3b ), supporting our finding of a rise in megakaryocytic differentiation in the presence of both effectors (Figure 1 ). Of note, SB, independently of PMA, increased c-mpl mRNA indicating that TPO receptor expression could be negatively regulated by the p38 MAPK pathway. GFX, as expected, was also shown to abrogate the positive and negative effects of PMA on megakaryocytic and erythroid differentiation, respectively.
Signaling pathways controlling megakaryocytic differentiation of K562 cells It is currently admitted that the effects of phorbol esters are mediated by conventional PKCs a, b1, b2, and g and new PKCs d, e, y, and Z, whose activation requires a relocation from the cytoplasm to the plasma membrane (Schaefer et al., 2001; Tanimura et al., 2002) . We used the latter feature to analyse the implication of new and conventional PKCs during megakaryocytic differentiation. Expression of the different PKC isoforms was therefore analysed by Western blot in cytoplasmic and microsomal fractions following treatment of K562 cells with PMA or the combination of PMA þ SB. Globally, 15 min following PMA stimulation, n and cPKCs disappeared from the cytoplasmic fraction concomitantly to their redistribution in the microsomal fraction ( Figure 4a ). SB by itself had no effect on PMA-induced PKCs relocation. Finally, using a pan phospho-PKC antibody, we also checked that relocated PKCs were active in the microsomal fraction. However, using tet-on K562 cells inducible for the expression of wild type or constitutively active PKC a, b, e, and y, we were unable to demonstrate that any of these PKC isotypes used alone can induce megakaryocytic differentiation (not shown). It is thus likely that more than one PKC isoform is required for the differentiation process. Finally, the lack of redistribution of PKCi, a PMAinsensitive isoform, is indicative of the specificity of the redistribution of novel and conventional PKCs by phorbol esters.
To further characterize the molecular events involved during megakaryocytic differentiation of K562 cells by PMA, we investigated the main signaling pathways potentially required for this process and more particularly Erk1/2, JNK, p38 MAPK and Akt activation. The phosphorylation status of these kinases is thought to represent a reliable index of their activity (Herrant et al., 2002) . In the absence of PMA, the significant activation of Erk1/2 can be explained by the presence in these cells of the constitutively activated Bcr-Abl chimaeric protein (Jacquel et al., 2003) (Figure 4b ). PMA was found to stimulate phosphorylation of Erk1/2, JNK and Akt at 30 min, an effect maintained for approximately 6 h, but inhibit p38 MAPK phosphorylation after 2 h of treatment ( Figure 4b ). In K562 cells stimulated with the combination of PMA and SB, there was a further increase in both Erk1/2 and JNK phosphorylation and no modification of the Akt phosphorylation status. Interestingly, GFX was found to abolish both the stimulatory effect of PMA on Erk1/2, JNK and Akt phosphorylation, and the inhibitory effect of the phorbol ester on p38 MAPK. Identical results were obtained using the MEG-01 CML cell line (not shown). Of note, the effect of SB was even more pronounced at the c-Jun phosphorylation level ( Figure 4b ). As higher concentrations of SB induced apoptosis and repressed megakaryocytic differentiation in the presence of PMA (Figure 2) , we analysed the effect of increasing concentrations of SB on Erk1/2, p38 MAPK, JNK activation, and c-Jun phosphorylation. Low doses of SB (1-5 mM) moderately increased JNK activation and c-Jun phosphorylation, while higher concentrations (20-40 mM) drastically induced phosphorylation of both proteins, an effect that correlates with increased cell death (Figures 2a and 4c) . Interestingly, potentialization of the PMA-mediated Erk1/2 activation by SB was reproduced in cells from a patient with CML ( Figure 4d ). Moreover, in primary CML cells, phosphorylation of Erk1/2 was very long lasting and still detected 120 h following the onset of PMA treatment. Altogether our results strongly suggest that megakaryocytic differentiation of K562 cells (i) involved new PKC isoforms, (ii) required activation of Erk1/2 and JNK, and inhibition of p38 MAPK and (iii) is independent of Akt activation. This conclusion is also supported by the two following observations: (i) GFX, U0126 (not shown) and high concentrations of SB (20-40 mM) that induced drastic JNK activation and apoptosis in the presence of PMA blocked megakaryocytic differentiation and (ii) low concentrations of SB which increased Erk1/2 and JNK activity and c-Jun phosphorylation and inhibited p38 MAPK without significantly affecting cell death favor this process. Finally, we checked that the PI3K inhibitors LY294002 and wortmannin (not shown) failed to affect megakaryocytic differentiation ruling out the possible involvement of the PI3K/Akt pathway in this process.
c-DNA array analysis of the effects of PMA on megakaryocytic differentiation To assess the effect of PMA on gene expression, we used a c-DNA array approach. We focused our attention on a limited number of selected genes (847), mainly involved in apoptosis, differentiation, angiogenesis, transcription, cell cycle, and signal transduction, all cellular processes involved in the regulation of cell fate. In total, 55 genes were found to be modulated by PMA either alone or in the presence of SB. Among them, eight were downregulated and 47 were upregulated (Table 1) . SB was found to increase the effect of PMA on the expression of most of these genes, either positively or negatively (not shown). Our c-DNA array approach was validated by the fact that, as expected, PMA increased Figure 3 Induction of megakaryocytic markers and repression of erythroid markers during differentiation of K562 cells by PMA. K562 cells were cultured 48 h in the presence of 10 ng/ml PMA, 1 mM GF109203X (GFX), 5 mM SB202190 (SB), or the combination PMA þ SB or PMA þ GFX. (a) Facs analysis of different differentiation markers: undifferentiated or 48 h differentiated K562 cells were incubated with saturating amount of either anti-CD44-FITC, anti-CD10-PE, or anti-CD41-FITC monoclonal antibodies for 30 min at 41C. Fluorescence was measured by using the FL1/FL2 channels of a FACScan. (b) RT-PCR: RT-PCR analysis of genes modulated in cells treated with 10 ng/ml PMA, 1 mM GF109203X (GFX), 5 mM SB202190 (SB), or the combination PMA þ SB or PMA þ GFX. Amplification method was described in Materials and methods. Actin and Bcr-Abl were used as invariant controls in the experiment.
Signaling pathways in leukemia cell differentiation A Jacquel et al the expression of megakaryocytic markers such as CD10, CD41 and, CD61 and decreased that of erythroid markers such as GPA, g-globin, and CD36 (Figures 3a and b, 5a and Table 1 ). The genes whose expression was increased or induced in this screening belong to different protein families including adhesion molecules (ICAM-1) and integrins such as a4, a5, aM, b1, b3, b5, b6, and b7, angiogenic factors (VEGF, VEGF-R1, and VEGF-R2, TIE-1, VRAP and angiopoietin), tyrosine kinase receptors (ephrin A4, B2, B6, AXL, and MPL-R), proteases and inhibitors (granzyme B, MMP-1 and 3, PAI, urokinase receptor, TIMP-1), chemokines and receptors (CCR7 and MCP-1) and transciption factors such as c-fos, stat-1, egr-1, RARe, notch 3 and 4, and Jun-B. Signaling pathways controlling megakaryocytic differentiation of K562 cells. (a) K562 cells were cultured for 15 min in the presence of 10 ng/ml PMA, 5 mM SB202190 or the combination of both effectors (PMA þ SB). Cell lysates were subfractionated in cytoplasmic and microsomal fractions, and proteins contained in each fraction were separated by electrophoresis on 10% polyacrylamide gels. Proteins were then blotted on to PVDF membranes with either anti-PKC a/b, g, e, d, i, anti-pan phospho PKC, or antiphospho Erk1/2 antibodies. (b) K562 cells were incubated for the times indicated in the presence of 10 ng/ml PMA, 1 mM GF109203X (GFX), 5 mM SB202190 (SB), or the combination PMA þ SB or PMA þ GFX. Cells lysates were separated by electrophoresis on 10% polyacrylamide gels. Proteins were then blotted on to PVDF membranes with either antiphospho Erk1/2, antiphospho p38 MAPK, antiphospho JNK, antiphospho Jun, antiphospho AKT and HSP60 antibodies. (c) K562 cells cultured for 6 h in the presence of 10 ng/ml PMA and/or various amounts of SB202190 (1-40 mM). Cell lysates were separated by electrophoresis on 10% polyacrylamide gels. Proteins were then blotted on to PVDF membranes with either antiphospho JNK or antiphospho Jun.
(d) Primary cells from a patient with chronic myeloid leukemia (Ph þ ) were treated for 48 or 120 h in the presence of 10 ng/ml PMA, 5 mM SB 202190, 10 mM Uo126, or the combination PMA þ SB or PMA þ Uo. After electrophoresis and transfer, proteins were then blotted on to PVDF membranes using an antiphospho Erk1/2.
Signaling pathways in leukemia cell differentiation A Jacquel et al While most of the modulated genes were found to be upregulated by PMA, expression of eight genes, namely, cyt-c, pentraxin 3, reelin, 5-lipooxygenase, cyclin A2 and D2, GAB-1 and transferin receptor was decreased. Among these latter genes, Reelin and 5-lipooxygenase have been previously shown to be increased during erythroid differentiation of K562 cells. Finally, many of the regulated genes detected in our screening have not been reported before to be modulated by PMA or during megakaryocytic differentiation. This is particularly true for ephrin receptors and angiogenic factors other than VEGF receptors. The regulation of some of these genes by PMA was confirmed by RT-PCR analysis (Figure 5a ). Finally, we also performed kinetic analysis of CD10, tie-1, glycophorin A, and actin mRNA expression upon PMA and PMA þ SB treatments. Interestingly, we confirmed that SB further increased the positive effect of PMA on CD10 and tie-1, and its negative effect on glycophorin A mRNA expression, respectively (Figures 3b and 5b ). As expected, we found no difference in actin mRNA expression whatever the conditions used to stimulate K562 cells.
RQ-PCR analysis of the expression of various transcription factors during megakaryocytic differentiation of K562 cells
The differentiation of the K562 leukemia cell line is under the control of transcription factors that can direct these cells specifically towards the erythroid or the megakaryocytic lineage. To analyse more precisely the effects of PMA and PMA þ SB on megakaryocytic differentiation, we evaluated by RQ-PCR the level of expression of more than 80 transcription factors. PMA was found to modulate the expression of at least ten transcription factors. Among them, nine (LKLF, c-Fos, Fos-B, Rel-B, Egr-1, Egr-2, c-Jun, Jun-B, and Blimp-1) were upregulated. Interestingly, SB was found to potentiate PMA effect on the expression of at least six of them (LKLF, Rel-B, C-Fos, Egr-1 and 2, and c-Jun), suggesting a role for these genes in favoring megakaryocytic differentiation in K562 cells. The expression of the three latter genes (Fos-B, Blimp-1, and jun-B) was not further modulated by SB. The potentiating effect of SB was even more pronounced on the expression of early immediate genes such as Egr-1 and 2 at 6 h (not shown). The expression of some other genes present in the assay including Cyclin D2 and c-Myc (not shown) was decreased by PMA and PMA þ SB in agreement with the c-DNA array analysis. Finally, we found that IEX-1 expression, a gene recently reported to be important for megakaryocytic differentiation (Garcia et al., 2002) , was induced by PMA, an effect clearly potentiated by SB. Altogether, our results linked the potentiating effect of SB on PMA-mediated megakaryocytic differentiation to the expression of several transcription factors such as LKLF, Rel-B, C-Fos, Egr-1 and 2, and c-Jun. Finally, none of the effectors significantly affected the expression of different housekeeping genes whatever the conditions used ( Figure 6 for HPRT and not shown). The list contains genes that showed over three-fold induction or repression in three different experiments as compared to control conditions (ratio of one). The ratio of gene expression in cells treated for 24 h with 10 ng/ml PMA is shown. a Genes also indicated in Figure 5 .
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Discussion
While it has been extensively reported that human CML K562 cells can be induced to differentiate towards the megakaryocytic lineage by PMA, the molecular mechanisms underlying such differentiation induction remain not completely deciphered. In the present study using both pharmacological, biochemical and c-DNA array analysis approaches, we explored in detail the pathways involved in PMA-mediated differentiation of K562 cells towards the megakaryocytic lineage.
It has been shown previously that PMA-induced megakaryocytic differentiation of K562 cells is dependent on the activity of the MEK/MAPK pathway (Melemed et al., 1997; Whalen et al., 1997; Herrera et al., 1998) . The data presented here confirm an important role of the MEK/Erk1/2 pathway in PMAinduced differentiation of K562 and also establish that the concomitant inhibition of the p38 MAPK pathway by PMA and a moderate activation of JNK also represent important determinants for complete (i.e. quantitative and qualitative) megakaryocytic differentiation of this cell line. This observation is supported by the finding that the p38 MAPK inhibitors SB202190 and SB203580 (not shown) considerably accelerated the kinetic and the extent of PMA-induced K562 cell differentiation allowing nearly 100% of cells to acquire a more pronounced megakaryocytic phenotype (Figure 1) . This potentiating effect of the p38 MAPK inhibitors seems to be due to both p38 MAPK inhibition and a significant activation of JNK and increased phosphorylation of c-Jun by these inhibitors (Figure 4) . Surprisingly, higher doses of SB202190, which drastically increased JNK activity, were nevertheless found to inhibit megakaryocytic differentiation of K562 and to induce cell death more especially in the presence of PMA. The effect of the combination of PMA and high doses of SB may appear somewhat surprising since PMA has been consistently shown to protect various cell lines against apoptosis (Bertolotto et al., 2000; Villalba et al., 2001; Herrant et al., 2002) . However, we have previously established that inhibition of the NFkB pathway, for example, can convert PMA from a death-protecting to a death-inducing function (Busuttil et al., 2002) . The drastic JNK activation achieved in the presence of high doses of SB may thus explain the considerable increase in caspase activation and apoptosis observed in the presence of PMA þ SB. p38 MAPK activation is thought to be a prerequisite for erythroid differentiation of K562 cells (Park et al., 2001) . As megakaryocytic and erythroid differentiation are mutually exclusive, it is noteworthy that PMA-mediated differentiation of K562 cells was accompanied by an inhibition of p38 MAPK activation and that p38 MAPK inhibitors can potentiate megakaryocytic differentiation of K562 cells. In line with our results, it has been recently reported that inhibition of p38 MAPK potentiates the JNK/SAPK pathway and AP-1 activity Signaling pathways in leukemia cell differentiation A Jacquel et al in monocytic differentiation of HL60 cells (Wang and Studzinski, 2001 ). The same authors previously demonstrated that 1,25 dihydroxyvitamin D 3 was able to block Ara-C-induced erythroid differentiation (Moore et al., 1991) . Therefore, it would be of interest to determine whether vitamin D 3 does increase megakaryocyte differentiation of K562 cells in the presence of PMA and whether inhibition of p38 MAPK is involved in this process.
A general role for PKCs in megakaryocytic differentiation induced by PMA has previously been established (Hong et al., 1996) . However, the specific PKC isotypes involved in this process, that is, conventional PKCs (cPKC) or new PKCs (nPKC), have not been 
Arbitrary unit
Arbitrary unit Arbitrary unit Figure 6 Real-time quantitative PCR. RNA was prepared from cells left untreated or treated for 24 h with 10 ng/ml PMA, 5 mM SB202190 or the combination of both effectors (PMA þ SB). The amplification method was described in the Materials and methods section.
Signaling pathways in leukemia cell differentiation A Jacquel et al characterized yet. Using a pharmacological approach, we demonstrated that new but not conventional PKCs are involved in this process since (i) GFX (an inhibitor of both cPKC and nPKC) abrogated PMA-induced differentiation of K562 cells as shown by both morphological assay and analysis of specific megakaryocytic markers, while (ii) Go6973 (an inhibitor of cPKC) had no effect (Figure 7) . To address the role of specific PKC isotypes in the differentiation process, we generated stable and inducible K562 cells (K562-tet-on) expressing dominant negative or constitutively active PKC a, b, e, and y. None of these isoforms alone were able to induce megakaryocytic differentiation of K562 cells or to potentiate PMA-induced differentiation (not shown). Thus, PMA-induced differentiation of K562 cells might depend on other PKC isotypes (not tested in the present study such as PKCg or PKCd) or more likely on a combination of two or more of these isotypes. Nevertheless, our results demonstrated that new PKCs rather than conventional PKCs mediated megakaryocytic differentiation of K562 cells. Megakaryocytic differentiation of K562 cells by PMA was only partly dependent on ERK/MAPK activity since it was significantly but not fully blocked by Uo126 and PD98059, two inhibitors of MEK1 (not shown). Accordingly, Shelly et al. (1998) reported that PMA triggered phenotypic changes in K562 cells by both MAPK-dependent and -independent events. In agreement with the involvement of other signaling pathways, we established that complete differentiation (i.e. quantitative and qualitative) of K562 cells towards the megakaryocytic lineage by PMA requires not only an inhibition of the p38 MAPK pathway but also a threshold of JNK and c-Jun activation (Figure 6a ). This is particularly evident from the experiments with the p38 MAPK inhibitors, which favor megakaryocytic differentiation in the low concentration ranges. It has been recently reported that the p38 MAPK pathway may provide negative feedback for Ras signaling (Chen et al., 2000 Signaling pathways in leukemia cell differentiation A Jacquel et al p38 MAPK pathway inhibited Ras activity by blocking activation of JNK, without however a direct effect upon Erk1/2. This effect was ultimately mediated by the p38 MAPK substrate, p38-related/activated protein kinase (PRAK). Such a negative feedback mechanism could provide a good explanation for the increase in differentiation observed in our study in the presence of SB, since blockade of p38 MAPK would remove the inhibitory effect on JNK, thus favoring megakaryocytic differentiation of K562 cells in the presence of PMA (Figure 7b ). PMA-induced differentiation of K562 cells is intimately associated with the expression of several genes (Alitalo, 1990; Cheng et al., 1994; Namciu et al., 1994; Belhacene et al., 1998; Jacquel et al., 2003) . To date, very few studies have analysed at a large scale (c-DNA array or DNA biochips) gene expression in K562 cells undergoing differentiation towards the megakaryocytic or erythroid lineage (Jacquel et al., 2003; Pettiford and Herbst, 2003; Huang et al., 2004) . It is well established that in vitro differentiation of K562 cells is characterized by morphological changes such as an increase in cell size and adhesion properties of the differentiating cells. In agreement with the latter finding, we detected by microarray analysis a drastic increase in several integrin subunits (Table 1) . Enhanced expression of CD41 and CD61 at the cell surface is commonly used as a hallmark of megakaryocytic differentiation, but besides these two markers, we identified several other integrins whose expression is induced by PMA and that have not yet been associated with this process. It seems likely that enhanced expression of these integrins is intimately linked to the increased adhesion observed in PMAtreated K562 cell cultures (not shown). Megakaryocytic differentiation of K562 cells also requires the activation of transcription factors that control the expression of specific genes in this lineage. In agreement with this statement, we found that PMA induced expression of different transcription factors known to be involved in megakaryocytic differentiation or associated with PMA stimulation such as c-Fos, B-Fos, Egr-1 and 2, Stat-1, Gata-2, c-jun, jun B, and Rel B (Table 1 , Figures 5 and  6 ). Interestingly, PMA also represses the expression of erythroid-specific transcription factors including Gfi-1B (Jacquel et al., 2003) . This profile of transcription factor and integrin expression is typical of megakaryocytic differentiation and thereby confirms the validity of our c-DNA array approach. Interestingly, we also detected in this screening the modulation of two other gene families that had never been described before to be induced or involved in megakaryocytic differentiation. First, we identified an increased expression of several angiogenic factors upon PMA treatment of K562 cells such as VEGF, VEGFR-1 and VEGFR-2, VRAP, TIE-1, and angiopoietin. Consistently, we have recently shown that K562 and CML cells from patients secrete a high amount of VEGF (Legros et al., 2004) . It is not known at present whether this specific profile of angiogenic gene expression is involved in the differentiation process or is rather a consequence of it. However, recent data from the literature have pointed out a role of VEGF as an autocrine factor for CML cell proliferation (Ruan et al., 2004) . Neoangiogenesis has also been shown to occur in the course of normal megakaryocytic differentiation and in this context increased expression of angiogenic factors in PMA-treated K562 cells makes sense.
It is noteworthy that differentiation of K562 cells towards the megakaryocytic lineage was also accompanied by induction or increased expression of Ephrin receptors. The Eph family of receptors constitutes the largest known family of tyrosine kinase receptors comprising not less than 14 members (Kullander and Klein, 2002; Poliakov et al., 2004) . Expression of Eph receptors is highly tissue specific and modulated in various pathological situations including cancer (Brantley-Sieders et al., 2004; Surawska et al., 2004) . To the best of our knowledge, a role of Eph receptors in leukemia cell differentiation has not yet been established. In a set of preliminary experiments, we have not been able to demonstrate a role of different recombinant Ephrins on megakaryocytic differentiation, but further studies are needed to confirm the potential role of Eph receptors in the differentiation program of K562 cells. Finally, the increase in AXL mRNA expression, which has also been confirmed at the protein level (not shown) during megakaryocytic differentiation of K562 cells is particularly interesting since members of the UFO/AXL receptor tyrosine kinase family are altered in a great variety of malignant phenotypes and Axl is widely associated with chronic myeloproliferative disorders and chronic myeloid leukemia (Neubauer et al., 1994) . Further studies are thus needed to assess more precisely the role of AXL and its ligand Gas 6 in megakaryocytic differentiation.
In conclusion, in the present study we have determined at the molecular level the requirements for PMA-induced differentiation of the K562 cell line towards the megakaryocytic lineage and evidenced by c-DNA microarray a set of new genes linked to this process. We showed that full differentiation of K562 cells by PMA towards the megakaryocytic phenotype required new PKC-dependent activation of Erk1/2 and JNK and inhibition of p38 MAPK. Next, we identified at least two gene families that had never been described before to be modulated or involved in this process. Notably, the observation of the induction of angiogenic factors, Ephrin, and AXL/UFO receptor genes during the course of megakaryocytic differentiation is of great interest since these two families of tyrosine kinase receptors seem intimately linked to differentiation processes and are also associated with leukomogenesis. In the near future, the involvement of these kinase families should be more globally addressed by selective silencing of the corresponding mRNA using RNA interference. In this line, stable K562 clones expressing inducible shRNA under the control of the tet promoter, which have been successively established in our laboratory for Bcr-Abl and Src kinases (not shown), should also be generated for the silencing of Eph and AXL/UFO receptor family members.
Materials and methods
Reagents and antibodies RPMI and fetal calf serum (FCS) were purchased from GIBCO BRL (Paisley, UK). Sodium fluoride, sodium orthovanadate, phenylmethylsulfonyl fluoride (PMSF), aprotinin, leupeptin, and Phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma (Saint-Louis, MO, USA). Bisindolylmaleimide-l (GF109203X), Go¨6976, Uo126, SB203190, SB202190, LY294002, and wortmannin were from Calbiochem (La Jolla, CA, USA). Anti-PKC a/b, g, e, d, and i were purchased from Transduction Laboratory (Lexington, KY, USA). Anti-pan phospho PKC, antiphospho Erk1/2, antiphospho p38 MAPK, antiphospho JNK, antiphospho c-Jun, antiphospho Akt, and peroxydase-conjugated anti-rabbit antibody were from Cell Signaling Technology (Beverly, MA, USA). Peroxidase-conjugated anti-mouse was from Dakopatts (Glostrup, Denmark).
Cell lines and human primary cells
The human cell line K562 and MEG-01 has been described elsewhere (Belhacene et al., 1998) and was cultured in RPMI 1640-glutamax supplemented with 5% FCS, 50 U/ml penicillin, 50 mg/ml streptomycin, and 1 mM pyruvate under 5% CO 2 in a humidified incubator. CML samples were obtained after approval by the institutional review board and appropriate informed consent from the patients. CML cells were cultured in RPMI 1640-glutamax supplemented with 10% FCS, 50 U/ml penicillin, 50 mg/ml streptomycin, and 1 mM pyruvate under 5% CO 2 in a humidified incubator.
Phase contrast microscopy K562 cells were treated for various times with PMA and different signaling inhibitors or the combination of both effectors. Morphologic changes characteristic of megakaryocytic differentiation were visualized using standard optics (Zeiss, Oberkochen, Germany). In some experiments, quantification of cells with megakaryocytic features was realized. To avoid potential errors in statistical sampling, fields were randomly selected and counts were performed by three different investigators in a blind manner.
Cytospin, May-Grunwald-Giemsa staining Approximatily 5 Â 10 4 cells were spun onto a microscope slide for 4 min at 800 g under medium acceleration in a cytospin 3. After air drying, slides were stained with May-GrunwaldGiemsa stain (Sigma) according to the manufacturer's instruction.
Electronic microscopy of control and differentiated cells Cells were fixed with 2% formaldehyde, in 0.1 M Na cacodylate, pH 7.4 for 1 h at 41C. Pellets were rinsed in cacodylate buffer, postfixed in 1% OsO4 for 1 h, dehydrated through graded alcohols, and embedded in epoxy resin. Oriented 1 mm sections were obtained with diamond knives and multiple areas were thin sectioned, mounted on copper mesh grids, and stained with uranyl acetate and lead citrate. Ultrathin sections were examined on a Jeol 1200 XII electron microscope.
Flow cytometry
To determine apoptosis, cells were treated and stained using the Antiactive-caspase-3-PE MAb Apoptosis Kit (BD Biosciences; San Diego, CA, USA). To determine megakaryocytic differentiation, cells were incubated to 41C for 30 min in 100 ml of PBS 0.1% bovine serum albumin (BSA) with monoclonal antibodies anti-CD44-FITC, and/or anti-CD41-FITC, and/or anti-CD10-PE (BD Biosciences; San Diego, CA, USA). After three washes with PBS, cells were fixed in 1% formaldehyde for 30 min at 41C. Fluorescence was measured by using the FL1 channel of a FACScan (Becton Dickinson; Cowley, UK).
RT-PCR Analysis
Isolation of RNA and RT-PCR has been described in detail elsewhere (Herrant et al., 2002) . To confirm differential mRNA expression, a panel of genes was quantified by RT-PCR using the following primers.
gel and transferred onto PVDF membrane (Immobilon-P, Millipore; Bedford, MA, USA). After blocking nonspecific binding sites, the membranes were incubated with specific antibodies. The membranes were washed three times with TNA-1% NP-40 (Tris 50 mM, NaCl 150 mM, pH 7.5) and incubated further with horseradish peroxidase conjugated antibody for 60 min at room temperature. Immunoblots were revealed by autoradiography using the enhanced chemiluminescence detection kit (Amersham Biosciences, Uppsala, Sweden).
Subcellular fractionnements
After stimulation, K562 cells (4 Â 10 6 ) were resuspended in hypotonic buffer containing 100 mM Tris-HCl pH 7.4, 5 mM EGTA, 1 mM PMSF, 1 mM leupeptin, and 20 mg/ml aprotinin, and rapidly sonicated at 41C. Cell extracts were first centrifuged at 2000 g for 10 min. Supernatants were then centrifuged at 100 000 g for 45 min. Soluble proteins (cytosol) were collected. Pellets (microsomal fraction) were lysed in buffer B. In each lane the amount of total, cytosolic, and microsomal proteins loaded on the gel corresponds to 4 Â 10 6 cells.
Expression array R&D Systems human Apoptosis Expression Array represents a comprehensive collection of genes implicated in apoptosis, cell cycle regulation, adhesion, differentiation, and signal transduction. The array consists of 847 different cloned cDNAs, printed as PCR products, on a positively charged nylon membrane. Total RNA was isolated using TriPure reagent (Boehringer Mannheim, Germany) from cells incubated for 24 h with the different effectors. PMA was used at 10 ng/ml. After purification, the total RNA pellets were resuspended in water and quantified using OD260 spectrophotometry (Perkin-Elmer MBA2000). Ribosomal RNA integrity was verified on a 1% agarose gel electrophoresis.
Probe synthesis was performed as previously described (Herrant et al., 2002) . Probes were hybridized to each array membrane for approximately 15 h in the Hybridization Solution at 651C. The array membranes were washed in decreasing concentrations of SSC. The damp arrays were exposed to a phosphor-imaging screen for 3-5 days. Exposed screens were scanned using a phosphor-imager STORM 840 (Molecular Dynamics). The images were analysed by the Image Quant 5.0 software essentially as previously described.
Real-time quantitative PCR Total RNA from cells was isolated from cells incubated for 24 h with the different effectors using the TRIzol reagent following the instructions of the manufacturer (Invitrogen).
After treatment with DNaseI, 1 mg of total RNA was reverse transcribed using random priming and Superscript II reverse transcriptase (Invitrogen). Real-time PCR was performed in an ABI PRISM 5700 Sequence Detector System (Applied Biosystems) using the SYBR Green detection protocol as outlined by the manufacturer. Gene-specific primers were designed using the Primer Express software (Applied Biosystems). Relative expression level of target genes was normalized for RNA concentrations with four different house-keeping genes (GAPDH, b-actin, HPRT and ubiquitin) . mRNA values are expressed as arbitrary units and represent the mean7s.d. of duplicates and are representative of two independent experiments.
